Brii Biosciences Limited Stock Price To Book

BRIBF Stock  USD 0.13  0.00  0.00%   
Brii Biosciences Limited fundamentals help investors to digest information that contributes to Brii Biosciences' financial success or failures. It also enables traders to predict the movement of Brii Pink Sheet. The fundamental analysis module provides a way to measure Brii Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brii Biosciences pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Brii Biosciences Limited Company Price To Book Analysis

Brii Biosciences' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Brii Biosciences Price To Book

    
  0.95 X  
Most of Brii Biosciences' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brii Biosciences Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, Brii Biosciences Limited has a Price To Book of 0.9537 times. This is 96.29% lower than that of the Healthcare sector and 84.21% lower than that of the Biotechnology industry. The price to book for all United States stocks is 89.97% higher than that of the company.

Brii Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brii Biosciences' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Brii Biosciences could also be used in its relative valuation, which is a method of valuing Brii Biosciences by comparing valuation metrics of similar companies.
Brii Biosciences is currently under evaluation in price to book category among its peers.

Brii Fundamentals

About Brii Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brii Biosciences Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brii Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brii Biosciences Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Brii Pink Sheet

Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.